Thumbnail

BILE DUCT CANCER (CHOLANGIOCARCINOMA) MARKET - PIPELINE INTELLIGENCE, 2019

Looking to buy the report?

Introduction

The bile duct cancer is rare, and can affect inside the liver (intrahepatic) and outside the liver (extrahepatic). The number of cases reported is lower. However, overall, the growth seems to be higher, as several patients with cancers are misdiagnosed to other types of cancers. As per the American Cancer Society, the disease is found to be most common among the Southeast Asian countries, due to parasitic infection, which can cause cancer in the bile duct region of the human body.

It is mostly being diagnosed in patients above the age of 60 years. In a majority of the cases, surgery is the only curative option, and there is no other approved treatment through drugs directly impacting the bile duct cancer. With a clear medical need for better local treatment of cancer, the opportunities in the development of drugs and therapies are likely to be high for this market, over the forecast period.

Report Coverage

This report by Mordor Intelligence provides extensive insights of the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world, are provided, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.

Bile Duct Cancer (Cholangiocarcinoma) Clinical Trial Analysis, by Phase and Status

  • The clinical trial analysis for bile duct cancer indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials and the ones terminated

Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information of registered clinical trials, in different countries, across several developed and emerging markets
  • In a majority of the cases, surgery is the only curative option, and there is no other approved treatment through drugs directly impacting the bile duct cancer. With a clear medical need for better local treatment of cancer, the opportunities in the development of drugs and therapies are likely to be high for this market, over the forecast period

Key Sponsors in Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you understand

  • The number of clinical trials that are being conducted worldwide
  • The key products that are under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Gather insights on regional and country-level data
  • Review of dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation, by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation, by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Other Statuses

8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy